NovaBridge Biosciences (NBP) EBT Margin (2019 - 2023)
NovaBridge Biosciences (NBP) posted quarterly EBT Margin of 738200.0% for Q4 2023, down 28185.25% on a QoQ basis from 2609.84% in Q3 2023.
NovaBridge Biosciences (NBP) EBT Margin (2019 - 2023) Analysis & Trends
NovaBridge Biosciences (NBP) has reported EBT Margin for 3 consecutive years, with 738200.0% the latest figure, recorded in Q4 2023.
- Quarterly EBT Margin changed N/A year-over-year to 738200.0% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 4361.77% (changed N/A YoY) and the FY2023 annual result came in at 13009.02%, down 391166.0% from the prior year.
- EBT Margin declined to 738200.0% in Q4 2023 per NBP's latest filing, from 2609.84% in the prior quarter.
- Over the last five years, EBT Margin for NBP reached as high as 5920.12% in Q4 2020 and fell as low as 738200.0% in Q4 2023.
- A 3-year average of 150772.42% and a median of 2609.84% in 2023 frame the typical range for EBT Margin.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | NovaBridge Biosciences | 389.86 Mn | 389.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -738,200.00% |
| Sep 30, 2023 | -2,609.84% |
| Jun 30, 2023 | -17,332.08% |
| Dec 31, 2020 | 5,920.12% |
| Sep 30, 2019 | -1,640.29% |